Leveraging on being small—Singapore's strategy to catalyze integrative innovations

Abstract

Microtechnology is not unfamiliar to Sin-gapore. Around the 1980s, Singapore es-tablished itself as one of the leading manufacturers of semiconductor micro-chips. Over the last 10 years, Singapore has established a biomedical research industry, epitomized by Biopolis, a two million square feet research campus. Biopolis is home to the national biomedical research institutes under the administration of the Agency of Science, Technology and Research (A*STAR), as well as corporate labs from GlaxoSmithKine (GSK), No-vartis and Eli Lily. A stone’s throw away is another major research hub, Fusionopolis, the physical science and engineering equivalent of Biopolis. Microtechnology also finds its way into this vibrant research community facilitating inter-disciplinary and translational research between biomedical and physical sciences. Other research centers, such as the Research Centres of Excellence initiated by the National Research Foundation, at the National University of Singapore and Nanyang Technological University are also in close proximity. Engineers or physical scientists need not look very far to find a myriad of opportunities to apply their technologies to help expedite biomedical sciences. Here, we feature a number of research centers where mi-crotechnologies are finding headway in advancing biomedical and fundamental sciences.